A 47-year-old non-smoker male who has received the first dose of the BNT162b2 mRNA Covid-19 vaccine in Saudi Arabia. At day 3 post-vaccination, he tested negative for Covid-19 and travelled to Egypt. On day 12 he developed runny nose, body ache and fever, and he reportedly tested (PCR) negative for Covid-19 Upon his return to Saudi on day 15, his symptoms have worsened and he presented to the Emergency Department, at which he tested positive for Covid-19. The patient was overweight (BMI = 29), was not suffering from any comorbidities and was not taking any medication. Upon examination, he was vitally stable and his laboratory investigation only revealed a slightly increased Creatinine. His chest X-ray was unremarkable. His condition did not require hospital admission, so he was discharged and advised to home-isolate himself. Four days after his discharge, his entire household came to the hospital and tested positive for Covid-19. This is the first case report, in Saudi Arabia, of a person receiving the first dose of the BNT162b2 vaccine and got infected with Covid-19 afterwards. The report highlights the significance of receiving the second dose of the vaccine to be effective. It also demonstrates that those with a single dose mRNA vaccine, could get infected and transmit the infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276583 | PMC |
http://dx.doi.org/10.1016/j.jiph.2021.07.006 | DOI Listing |
Front Immunol
January 2025
Faculty of Medicine, University of Castilla-La Mancha, Albacete, Spain.
Introduction: Despite the efficacy and safety of SARS-CoV-2 vaccines, inflammatory and/or thrombotic episodes have been reported. Since the impact of COVID-19 vaccines on the endothelium remains uncertain, our objective was to assess endothelial activation status before and 90 days after the third dose of the BNT162b2 mRNA COVID-19 vaccine.
Methods: A prospective longitudinal study was conducted at University General Hospital of Albacete, involving 38 healthy health-care workers.
Nat Hum Behav
January 2025
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Healthcare use among adolescents after vaccination against SARS-CoV-2 is unknown. In a real-life register-based cohort study (trial NCT04786353), healthcare use was compared among Pfizer-BioNTech BNT162b2 COVID-19 vaccinated and unvaccinated 12-18-year-olds. First-dose-vaccinated (between 1 May and 30 September 2021) adolescents were sex and age matched 1:1 with unvaccinated adolescents.
View Article and Find Full Text PDFCommun Med (Lond)
January 2025
URC EST, Sorbonne Université, Paris, France.
Background: We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech).
View Article and Find Full Text PDFJ Infect
January 2025
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Pandemic Sciences Institute, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford, UK.
Objectives: Evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2.
Methods: COV009 is a safety follow-up study of volunteers enrolled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19.
Lancet Infect Dis
January 2025
Novavax, Gaithersburg, MD, USA.
Background: Authorities globally recommended a monovalent omicron XBB.1.5-based COVID-19 vaccine for the 2023-24 season.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!